A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody

World Journal of Gastroenterology

Volumn 14, Issue 45, 2008, Pages 7012-7015

  Xu, Jin ^a   Yang, Chuan Hua ^a   Chen, Xiao Yu ^a   Li, Xu Hang ^b   Dai, Min ^a   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chinese medicine; Methyprednisolone; Proteinase 3 antineutrophil cytoplasmic antibody; Refractory ulcerative colitis; Steroid dependence

Indexed keywords

AZATHIOPRINE; CHINESE DRUG; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOODY DIARRHEA; CLINICAL ARTICLE; CLINICAL FEATURE; COLON MUCOSA; COLON RESECTION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; RECTUM MUCOSA; RECURRENT DISEASE; REMISSION; ULCERATIVE COLITIS;

EID: 63449113741     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.7012     Document Type: Article

References (13)

1. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; CD004277
2. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; CD000478
3. Geffriaud-Ricouard C, Noel LH, Chauveau D, Houhou S, Grunfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39: 125-136
4. Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int 2007; 56: 87-96
5. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44
6. de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 2005; 64: 480-484
7. Rump JA, Scholmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, Ludemann J, Gross WL, Peter HH. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990; 181: 406-413
8. Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1992; 33: 668-674
9. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-791
10. Liu X, Yu T, Zhao M, Tang X, Gu Q, Liu N. [The diagnostic significance of antineutrophil cytoplasmic antibodies in ulcerative colitis] Zhonghua Neike Zazhi 1999; 38: 451-454
11. Elzouki AN, Eriksson S, Lofberg R, Nassberger L, Wieslander J, Lindgren S. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis 1999; 5: 246-252
12. Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 2003; 52: 377-382
13. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476